How to Get Retatrutide in 2026
Last updated:
Retatrutide's Phase 3 obesity trial is published: a −25.0% mean change in body weight at 12 mg over 80 weeks in TRIUMPH-1 (NEJM 2026), after 24.2% at 48 weeks in Phase 2. It's not FDA-approved yet (Lilly plans to submit in Q1 2027), and the FDA says it cannot legally be compounded. Here's everything you need to know about legal status, why it can't be compounded, and what to realistically expect.
TRIUMPH-1 published
TRIUMPH-1, 12mg/80wk
Optimistic scenario
Retatrutide is not yet FDA-approved, so there is no retail prescription version in 2026. In the US, the lawful way to get it before approval is a clinical trial. The FDA says retatrutide cannot be used in compounding under federal law, and it has warned companies selling it (FDA). Approved alternatives exist today: tirzepatide (Zepbound), semaglutide (Wegovy injection or tablets) and orforglipron (Foundayo).
What Makes Retatrutide Different
Retatrutide is a GLP-1/GIP/glucagon triple agonist — it hits all three receptors simultaneously. That's one more than tirzepatide (which only hits GLP-1 and GIP).
GLP-1 (satiety, glucose), GIP (insulin, fat storage), and glucagon (fat burning, metabolism).
In the Phase 2 trial (N=338; PMID 37366315), 24.2% body weight reduction at 12mg dose over 48 weeks. Phase 3 TRIUMPH-1 (2,339 participants, NEJM 2026) reported −25.0% at 12mg over 80 weeks vs −3.9% with placebo (PMID 42814954).
Lilly's Phase 3 program includes the TRIUMPH obesity trials and separate trials in type 2 diabetes. Lilly's Q2 2026 results say the clinical data package is complete for obesity, obstructive sleep apnea and knee osteoarthritis pain, with an FDA submission planned for Q1 2027. Approval timing then depends on FDA review.
Retatrutide is under clinical development for type 2 diabetes, obesity and related complications (PMID 42250575). It has no FDA label yet, so its approved uses are not set.
Where Retatrutide Is in Approval
Understanding the regulatory timeline helps set realistic expectations for when commercial access arrives.
Your Options Before Approval
What is and is not legal before FDA approval, based on FDA statements.
The FDA states that retatrutide cannot be used in compounding under federal law: it is not a component of any FDA-approved drug and has not been found safe and effective for any condition (FDA statement). In a 2025 warning letter the agency explained it is not eligible under section 503A (no USP/NF monograph, not in an approved drug, not on the 503A bulks list) or 503B (not on the 503B bulks list or the drug shortage list) (FDA warning letter). The shortage-era rules that allowed compounded semaglutide and tirzepatide do not apply to an unapproved drug.
Some websites sell retatrutide labeled "for research purposes" or "not for human consumption." The FDA has warned companies selling such products directly to consumers for human use, calls them unapproved drugs of unknown quality, and urges consumers not to buy them (FDA). There is no medical oversight and no regulator checks what is in the vial.
The lawful route to retatrutide before approval. Search ClinicalTrials.gov for retatrutide studies that are currently recruiting near you. Benefits: study drug at no cost and close medical monitoring. Downsides: you may be assigned placebo, strict inclusion/exclusion criteria, frequent visits.
Be wary of any seller or clinic that offers "compounded retatrutide" (the FDA says it cannot be compounded), claims retatrutide is FDA-approved (it is not), or sells it with dosing instructions under a "research use" label. The FDA has issued warning letters to telehealth companies, ingredient distributors and outsourcing facilities over retatrutide (FDA).
What to Ask Your Doctor
Retatrutide has no FDA label, so it cannot be prescribed "off-label" or compounded. The useful conversation is about trials and approved options.
"Am I a candidate for a retatrutide clinical trial?" / "My BMI is [X] and I've had limited success with [previous approaches] — is an approved option such as Zepbound, Wegovy or Foundayo right for me now?" / "What should we monitor (bloodwork, muscle mass, side effects)?" Lead with the data, not the desire.
FDA-approved weight-management drugs include tirzepatide (Zepbound), semaglutide (Wegovy injection and Wegovy tablets) and orforglipron (Foundayo). Labels generally cover adults with obesity, or overweight with at least one weight-related condition. Insurance coverage varies by plan.
Bottom Line
- Ask your doctor whether an approved GLP-1 (Zepbound, Wegovy, Foundayo) fits you now
- Search ClinicalTrials.gov for retatrutide trials that are recruiting
- Wait for an FDA decision: Lilly plans to submit in Q1 2027
- Get baseline bloodwork (HbA1c, lipids, glucose, liver enzymes)
- FDA says retatrutide cannot be compounded under federal law
- "Research use only" retatrutide is an unapproved drug the FDA warns consumers not to buy
- TRIUMPH-1 is published (−25.0% at 12 mg over 80 weeks), but there is no FDA label yet, so approved doses and warnings are still unknown
- Medical monitoring matters — GI side effects, muscle loss, and gallstones need management
- No drug beats lifestyle — retatrutide is a tool, not a substitute
🛒 Recommended Supplies
Supplies for anyone on a prescribed weekly GLP-1 injection.
Affiliate links — support HighPeptides at no extra cost.
🔬 Research Peptide Supplier — Not a Retatrutide Route
Swiss Chems
Swiss Chems is our affiliate partner for research-use-only peptides. It is not a way to get retatrutide for personal use: as covered above, the lawful route before approval is a clinical trial, and approved alternatives are available by prescription. The vendor says it publishes third-party HPLC test results (COAs) for its products.
Browse Swiss Chems →Affiliate links — support HighPeptides at no extra cost.
This content is for educational and informational purposes only. Retatrutide is not FDA-approved for human use. Nothing on this page constitutes medical advice. Consult a qualified healthcare provider before using any GLP-1 drug or peptide. The authors are not responsible for any health outcomes resulting from use of information on this page.
Key Takeaways
✅ What We Know
- ✅Retatrutide is a triple agonist (GLP-1/GIP/glucagon), which Lilly calls first-in-class
- ✅Phase 3 TRIUMPH-1 (NEJM 2026): −25.0% mean body weight change at 12 mg over 80 weeks (24.2% at 48 weeks in Phase 2)
- ✅Phase 3 results published; not yet FDA-approved (Eli Lilly plans to submit in Q1 2027)
- ✅In the US, available through clinical trials until FDA approval; FDA says it cannot be compounded
⚠️ What We Don't Know
- ⚠️No FDA label yet — final approved doses, warnings and indications await FDA review
- ⚠️Long-term safety profile still being established
- ⚠️Optimal dosing for maintenance not yet determined
- ⚠️Insurance coverage unlikely until FDA approval
🛒 Recommended Products
Relevant supplies for GLP-1 peptides.
Affiliate links — support HighPeptides at no extra cost.
⚕️ Disclaimer
This page is for educational and informational purposes only. It is not medical advice. Always consult with a qualified healthcare provider before starting any supplement or medication. Data sourced from published peer-reviewed research. HighPeptides may receive affiliate compensation from linked vendors.
47-page guide: protocols, dosing, sourcing — everything in one place.
Get the guide — $19 (normally $29) → New to peptides? Start with the $19 Buyer’s Playbook → All ebooks & guides →Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.